© 2000 by European Society of Cardiology
REVIEW
Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview
Division of Cardiology, St Michael's Hospital Toronto, Ontario, Canada
Prolongation of the cardiac action potential and refractoriness (class III effect) is a potentially beneficial electrophysiological mechanism of action. However, this effect may be diminished or eliminated at rapid heart rates, so-called ‘reverse rate dependence’ of prolongation of repolarization.
Action potential duration normally shortens as heart rate increases, due to increases in outward repolarizing currents, and/or decreases in inward depolarizing currents. The assessment of the effect of drugs on action potential duration is complicated by inter-species differences in ionic currents mediating repolarization, heterogeneity within the heart in repolarizing currents, and differential effect of drugs in different species, during differing experimental conditions, and at different rates of stimulation.
In general, most drugs which predominantly block the IKrrepolarizing current exhibit reverse rate-dependent effects on cardiac repolarization. Drugs or combinations of drugs which produce multiple ionic channel blocks and possibly those which block the IKscurrent, may be less prone to this potentially undesirable effect.
Key Words: Antiarrhythmic agents, refractory periods, rate dependence
Correspondence: Dr P. Dorian, Division of Cardiology, St Michael's Hospital, 30 Bond Street, Room 7-051Q, Toronto, Ontario, Canada, M5B 1W8.
[1] Klein RC. Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial. Eur Heart J 1993; 14: 78–84.[Abstract]
[2] Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92: 3264–3272.
[3] Antz M, Cappato R, Kuck KH. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. J Cardiovasc Pharmacol 1995; 26: 627–635.[Web of Science][Medline]
[4] Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348: 7–12.[CrossRef][Web of Science][Medline]
[5] Bloch-Thomsen P. DIAMOND (Danish Investigations of Arrhythmia and Mortality on Dofetilide). Clin Cardiol 1998; 21: 53–54.
[6] Hondeghem LM and Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81: 686–690.
[7] Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990; 82: 2235–2242.
[8] Sada H, Ban T, Oshita S. Effects of mexiletine on transmembrane action potentials as affected by external potassium concentration and by rate of stimulation in guinea pig papillary muscles. Clin Exp Pharmacol Physiol 1980; 7: 583–593.[Web of Science][Medline]
[9] Campbell TJ. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983; 17: 344–352.[Web of Science][Medline]
[10] Nattel S and Zeng FD. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1984; 229: 283–291.
[11] Carmeliet E. Repolarisation and frequency in cardiac cells. J Physiol 1977; 73: 903–923.
[12] Boyett MR and Fedida D. Changes in the electrical activity of dog cardiac Purkinje fibres at high heart rates. J Physiol (Lond) 1984; 350: 361–391.
[13] Janvier NC and Boyett MR. The role of Na-Ca exchange current in the cardiac action potential. Cardiovasc Res 1996; 32: 69–84.[CrossRef][Web of Science][Medline]
[14] Williams BA, Dickenson DR, Beatch GN. Kinetics of rate-dependent shortening of action potential duration in guinea-pig ventricle; effects of IK1and IKrblockade. Br J Pharmacol 1999; 126: 1426–1436.[CrossRef][Web of Science][Medline]
[15] Li GR and Nattel S. Properties of human atrial ICaat physiological temperatures and relevance to action potential. Am J Physiol 1997; 272: H227–235.[Web of Science][Medline]
[16] Courtemanche M, Ramirez RJ, Nattel S. Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol 1998; 275: H301–321.[Web of Science][Medline]
[17] Franz MR and Costard A. Frequency-dependent effects of quinidine on the relationship between action potential duration and refractoriness in the canine heart in situ. Circulation 1988; 77: 1177–1184.
[18] Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993; 88: 1063–1071.
[19] Lee RJ, Liem LB, Cohen TJ, Franz MR. Relation between repolarization and refractoriness in the human ventricle: cycle length dependence and effect of procainamide. J Am Coll Cardiol 1992; 19: 614–618.[Abstract]
[20] Zaza A, Malfatto G, Schwartz PJ. Sympathetic modulation of the relation between ventricular repolarization and cycle length. Circ Res 1991; 68: 1191–1203.
[21] Malfatto G, Zaza A, Schwartz PJ. Parasympathetic control of cycle length dependence of endocardial ventricular repolarisation in the intact feline heart during steady state conditions. Cardiovasc Res 1993; 27: 823–827.
[22] Franz MR, Swerdlow CD, Liem LB, Schaefer J. Cycle length dependence of human action potential duration in vivo. Effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest 1988; 82: 972–979.[Web of Science][Medline]
[23] Morady F, Kadish AH, Toivonen LK, Kushner JA, Schmaltz S. The maximum effect of an increase in rate on human ventricular refractoriness. Pacing Clin Electrophysiol 1988; 11: 2223–2234.[CrossRef][Medline]
[24] Dawodu AA, Monti F, Iwashiro K, Schiariti M, Chiavarelli R, Puddu PE. The shape of human atrial action potential accounts for different frequency-related changes in vitro. Int J Cardiol 1996; 54: 237–249.[CrossRef][Web of Science][Medline]
[25] Antzelevitch C, Sicouri S, Litovsky SH. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991; 69: 1427–1449.
[26] Rosenbaum DS, Kaplan DT, Kanai A. Repolarization inhomogeneities in ventricular myocardium change dynamically with abrupt cycle length shortening. Circulation 1991; 84: 1333–1345.
[27] Laurita KR, Girouard SD, Rosenbaum DS. Modulation of ventricular repolarization by a premature stimulus. Role of epicardial dispersion of repolarization kinetics demonstrated by optical mapping of the intact guinea pig heart. Circ Res 1996; 79: 493–503.
[28] Liu DW and Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKscontributes to the longer action potential of the M cell. Circ Res 1995; 76: 351–365.
[29] Bauer A, Becker R, Freigang KD. Rate- and site-dependent effects of propafenone, dofetilide, and the new IKs-blocking agent chromanol 293b on individual muscle layers of the intact canine heart. Circulation 1999; 100: 2184–2190.
[30] Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954–1968.
[31] Daoud EG, Bogun F, Goyal R. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94: 1600–1606.
[32] Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 1998; 98: 2202–2209.
[33] Franz MR, Karasik PL, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997; 30: 1785–1792.[Abstract]
[34] Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512–525.
[35] Yu WC, Chen SA, Lee SH. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation 1998; 97: 2331–2337.
[36] Li C, Newman D, Qi X, Dorian P. The effect of ventricular fibrillation and defibrillation on action potential duration. Can J Cardiol 1995; 11: 96E.
[37] Fermini B, Wang Z, Duan D, Nattel S. Differences in rate dependence of transient outward current in rabbit and human atrium. Am J Physiol 1992; 263: H1747–1754.[Web of Science][Medline]
[38] Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1061–1076.
[39] Iost N, Lengyel C, Virág L, Varró A, Papp JG. Does IKsplay an important role in rabbit cardiac repolarization? [abstract]. Pacing Clin Electrophysiol 2000; 23: 661.
[40] Varró A, Baláti B, Iost N. The role of the delayed rectifier component IKsin dog ventricular muscle and Purkinje fibre repolarization. J Physiol 2000; 523: 67–81.
[41] Bosch RF, Gaspo R, Busch AE, Lang HJ, Li GR, Nattel S. Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res 1998; 38: 441–450.
[42] Groh WJ, Gibson KJ, Maylie JG. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation. J Cardiovasc Electrophysiol 1997; 8: 529–536.[Web of Science][Medline]
[43] Baskin EP and Lynch JJ Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther 1998; 285: 135–142.
[44] Jurkiewicz NK and Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+current by dofetilide. Circ Res 1993; 72: 75–83.
[45] Gjini V, Korth M, Schreieck J, Weyerbrock S, Schomig A, Schmitt C. Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. J Cardiovasc Pharmacol 1996; 28: 314–320.[CrossRef][Web of Science][Medline]
[46] Bril A, Forest MC, Cheval B, Faivre JF. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. Cardiovasc Res 1998; 37: 130–140.
[47] Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998; 37: 627–635.
[48] Schreieck J, Wang Y, Gjini V. Differential effect of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J Cardiovasc Electrophysiol 1997; 8: 1420–1430.[Web of Science][Medline]
[49] Franz MR. Bridging the gap between basic and clinical electrophysiology: what can be learned from monophasic action potential recordings? J Cardiovasc Electrophysiol 1994; 5: 699–710.[Web of Science][Medline]
[50] Franz MR, Chin MC, Sharkey HR, Griffin JC, Scheinman MM. A new single catheter technique for simultaneous measurement of action potential duration and refractory period in vivo. J Am Coll Cardiol 1990; 16: 878–886.[Abstract]
[51] Sager PT and Behboodikhah M. Frequency-dependent electrophysiologic effects of d,l-sotalol and quinidine and modulation by beta-adrenergic stimulation. J Cardiovasc Electrophysiol 1996; 7: 102–112.[Web of Science][Medline]
[52] Lee SD, Newman D, Ham M, Dorian P. Electrophysiologic mechanisms of antiarrhythmic efficacy of sotalol and class Ia drug combination: elimination of reverse use dependence. J Am Coll Cardiol 1997; 29: 100–105.[Abstract]
[53] Newman D, Dorian P, Feder-Elituv R. Isoproterenol antagonizes drug-induced prolongation of action potential duration in humans. Can J Physiol Pharmacol 1993; 71: 755–760.[Web of Science][Medline]
[54] Sager PT. Modulation of antiarrhythmic drug effects by beta-adrenergic sympathetic stimulation. Am J Cardiol 1998; 82: 201–301.
[55] Sager PT, Follmer C, Uppal P, Pruitt C, Godfrey R. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans. Circulation 1994; 90: 1811–1819.
[56] Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PK. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action, Circ Res 1991; 68: 77–84.
[57] Groh W and Maylie J. Efficacy of NE-10064 in maintaining repolarizing current block after d,l-sotalol and isoproterenol. Pacing Clin Electrophysiol 1994; 17: 755.
[58] Boutitie F, Boissel JP, Connolly SJ. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99: 2268–2275.
[59] Nattel S. Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 1998; 37: 567–577.
[60] Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349: 675–682.[CrossRef][Web of Science][Medline]
[61] Julian DG, Camm AJ, Frangin G. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349: 667–674.[CrossRef][Web of Science][Medline]
[62] Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997; 96: 2823–2829.
[63] Huikuri HV and Yli-Mayry S. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle. Pacing Clin Electrophysiol 1992; 15: 2103–2107.[CrossRef][Medline]
[64] Naitoh N, Furushima H, Ohira K, Taneda K, Aizawa Y. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle. Jpn Heart J 1998; 39: 153–161.[Medline]
[65] Schmitt C, Brachmann J, Karch M. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol 1991; 68: 1183–1187.[CrossRef][Web of Science][Medline]
[66] Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992; 70: 1432–1437.[CrossRef][Web of Science][Medline]
[67] Demolis JL, Funck-Brentano C, Ropers J, Ghadanfar M, Nichols DJ, Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 64: 1592–1599.
[68] Sager P. Frequency-dependent electrophysiological effects of dofetilide in humans [abstract]. Circulation 1995; 92: I774.
[69] Naitoh N, Tagawa M, Yamaura M, Taneda K, Furushima H, Aizawa Y. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias. Jpn Heart J 1998; 39: 457–467.[Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. N. Singh Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1_suppl): S13 - S26. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||